Nasdaq: ODTX · IPO announced
Odyssey Therapeutics IPO
Odyssey Therapeutics (ODTX) announced an IPO on Jan 17, 2025. The price range is not set. The listing date is not set.
Last session · Nov 18, 2026
- Market cap
- $912.33M
- from the ticker reference
- Volume
- 302.03K
- shares, regular session
- VWAP
- $19.24
- the last price is -1.37% from the volume-weighted average
- Day range
- 18.81–19.98
- low to high
The trading numbers are from the last session, Nov 18, 2026.
The offering
The terms of the Odyssey Therapeutics IPO.
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Where ODTX ranks
Odyssey Therapeutics's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- ODTX$912.33M
Filings and the company
What Odyssey Therapeutics has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Odyssey Therapeutics discloses to the SEC on Form 8-K.
- Quarterly earningsNov 4, 2026
On November 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended September 30, 2026.
- Investor presentationOct 20, 2026
The Company issued the press release and “posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations.”
- Investor presentationSep 9, 2026
On September 8, 2026, Odyssey Therapeutics, Inc. (the "Company") posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
- Investor presentationJun 23, 2026
On June 23, 2026, Odyssey Therapeutics, Inc. (the "Company") posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
- Charter amendmentMay 11, 2026
In connection with the closing of the IPO, on May 11, 2026, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware. The Company's board of directors and stockholders previously approved the Amended and Restated Certificate of Incorporation to be effective as of immediately prior to the closing of the IPO.
About Odyssey Therapeutics
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
- Ticker
- ODTX
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Listed
- May 8, 2026
- Security
- Ordinary Shares
Frequently asked questions
What is the Odyssey Therapeutics IPO price?
It is not set. No price range is public yet.
When does Odyssey Therapeutics (ODTX) start trading?
The listing date for ODTX is not set.
Are the prices on this page real time?
No. Prices on this page are delayed 15 minutes. The Massive API and MCP server provide the most current data.
Build with Massive
Get the ODTX data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/ODTX/range/5/minute |
| Market cap | /v3/reference/tickers/ODTX |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.